Natera CEO Chapman sells $978,677 in company stock

Published 20/03/2025, 02:48
Natera CEO Chapman sells $978,677 in company stock

Steven Leonard Chapman, the CEO and President of Natera, Inc. (NASDAQ:NTRA), has recently sold 6,702 shares of the company’s common stock. The transaction, which took place on March 17, 2025, was conducted at an average price of $146.03 per share, resulting in a total value of approximately $978,677. The stock, currently trading at $150.87, has demonstrated strong momentum with a 62.4% return over the past year, according to InvestingPro data.

Following this sale, Chapman holds 203,354 shares directly. The transaction was partly executed to meet tax withholding and remittance obligations related to the vesting of restricted stock units (RSUs). This sale was carried out under a pre-arranged trading plan, in compliance with Rule 10b5-1(c) under the Exchange Act, as per the company’s stock unit agreement. With a market capitalization of $20.41 billion and an overall "GOOD" Financial Health rating from InvestingPro, investors can access detailed insider trading analysis and 11 additional ProTips through the platform’s comprehensive research reports.

In other recent news, Natera has reported a strong fourth-quarter performance for 2024, with revenue reaching $476 million, a 53% increase from the previous year, surpassing the forecasted $409.89 million. The company’s earnings per share were reported at -$0.41, better than the anticipated -$0.49. Natera’s gross margins improved to 63%, reflecting enhanced operational efficiencies. In another development, Natera has initiated the HEROES clinical trial in France to explore therapy de-escalation in metastatic HER2+ breast cancer patients, funded by the French Ministry of Health.

TD Cowen has maintained a Buy rating for Natera, setting a price target of $195, highlighting the company’s promising 2025 sales guidance, which exceeds consensus estimates by about 5%. Analysts noted the potential for increased sales and higher gross margins as key growth drivers. Similarly, Canaccord Genuity has raised its price target for Natera from $180 to $195, following the company’s fourth-quarter results, which exceeded preliminary estimates. The firm is optimistic about Natera’s revenue growth prospects in 2025, particularly due to improved Medicare Advantage rates and expected biomarker legislation.

Natera’s strategic spending on operational expenses is noted to fuel growth, despite impacting gross margins. The company has achieved positive operating cash flows for the fourth consecutive quarter, indicating consistent financial performance. These developments signify Natera’s robust position in the genetic testing and diagnostics sector, with ongoing efforts to expand its market presence and improve financial metrics.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.